R
Robert Dorkin
Researcher at Alnylam Pharmaceuticals
Publications - 2
Citations - 783
Robert Dorkin is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Gene silencing & Small interfering RNA. The author has an hindex of 2, co-authored 2 publications receiving 720 citations.
Papers
More filters
Journal ArticleDOI
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky,Aldo Grefhorst,Norma N. Anderson,Timothy Racie,Birgit Bramlage,Akin Akinc,David Butler,Klaus Charisse,Robert Dorkin,Yupeng Fan,Christina Gamba-Vitalo,Philipp Hadwiger,Muthusamy Jayaraman,Matthias John,K. Narayanannair Jayaprakash,Martin Maier,Lubomir Nechev,Kallanthottathil G. Rajeev,Timothy Read,Ingo Röhl,Jürgen Soutschek,Pamela Tan,Jamie Wong,Gang Wang,Tracy Zimmermann,Antonin de Fougerolles,Hans-Peter Vornlocher,Robert Langer,Daniel G. Anderson,Muthiah Manoharan,Victor Koteliansky,Jay D. Horton,Kevin Fitzgerald +32 more
TL;DR: PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc is validated, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.
Journal ArticleDOI
Kinome-wide RNAi screen implicates at least 5 host hepatocyte kinases in Plasmodium sporozoite infection.
Miguel Prudêncio,Cristina Rodrigues,Cristina Rodrigues,Michael Hannus,Cecilie Martin,Eliana Real,Lígia A. Gonçalves,Celine Carret,Robert Dorkin,Ingo Röhl,Kerstin Jahn-Hoffmann,Adrian J. F. Luty,Robert Sauerwein,Christophe Echeverri,Maria M. Mota,Maria M. Mota +15 more
TL;DR: This study represents the first comprehensive, functional genomics-driven identification of novel host factors involved in Plasmodium sporozoite infection and indicates a role for host PKCς on the invasion of hepatocytes by sporozoites.